Innovation in health care: a call to action.

Ann Pharmacother

Practice and Public Policy Partnerships, School of Pharmacy, University of Connecticut, Storrs, CT, USA.

Published: September 2011

Innovation in health care is difficult yet necessary in this era of health care delivery and payment reform. The Center for Medicare and Medicaid Services (CMS) Innovation Center and the CMS Partnership for Patients have announced priority areas to achieve better health, better care, and reduced costs through continuous improvement. Pharmacists possess the therapeutic knowledge and medication process expertise to create collaborative and innovative solutions that address medication use and safety problems. As a profession, we face a call to action. As pharmacy practitioners, educators, and researchers, we face an unprecedented opportunity to make a difference. So, either individually or collectively in our workplaces and pharmacist professional organizations, we must respond to this call to action. Some practical suggestions are offered to get us started on this journey.

Download full-text PDF

Source
http://dx.doi.org/10.1345/aph.1Q262DOI Listing

Publication Analysis

Top Keywords

health care
12
call action
12
innovation health
8
care
4
care call
4
action innovation
4
care difficult
4
difficult era
4
era health
4
care delivery
4

Similar Publications

Trends and predictors of leaving before medically advised in US emergency departments from 2016 to 2021.

Am J Emerg Med

December 2024

Department of Health Policy & Organization, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL, USA; Center for Outcomes and Effectiveness Research and Education, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.

Background: Leaving before medically advised (BMA) is a significant issue in the US healthcare system, leading to adverse health outcomes and increased costs. Despite previous research, multi-year studies using up-to-date nationwide emergency department (ED) data, are limited. This study examines factors associated with leaving BMA from EDs and trends over time, before and during the COVID-19 pandemic.

View Article and Find Full Text PDF

India's National COVID Vaccination Program recommended vaccination of children ages 6-12 years in April 2022. This study assessed vaccine acceptance among mothers to better understand potential barriers and facilitators of national acceptance of pediatric coronavirus disease 2019 (COVID-19) vaccination. Qualitative data were collected through three focus group discussions (FGDs) with mothers who had children younger than 12 years of age; FGD-1 was composed of mothers who worked at a tertiary medical center in India, whereas FGD-2 and FGD-3 were composed of mothers who sought care at urban and rural community health centers.

View Article and Find Full Text PDF

Melioidosis is a neglected tropical infection caused by the Gram-negative bacterium Burkholderia pseudomallei, which is found in soil and water across tropical countries. The infection spectrum ranges from mild localized lesions to severe sepsis. The clinical presentation, severity, and outcome are influenced by the route of infection, bacterial load, strain virulence, and specific virulence genes of B.

View Article and Find Full Text PDF

How I Treat Higher-Risk MDS.

Blood

January 2025

H. Lee Moffitt Cancer Center, Tampa, Florida, United States.

Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival.

View Article and Find Full Text PDF

BTK inhibitors (BTKi) are an established standard of care in CLL. The covalent BTKi ibrutinib, acalabrutinib and zanubrutinib bind to BTK C481 and are all susceptible to the C481S mutation. Non-covalent BTKi including pirtobrutinib overcome C481S resistance but are associated with multiple variant (non-C481) BTK mutations, including those associated with resistance to acalabrutinib and zanubrutinib (T474 codon and L528W mutations).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!